Why the study?
Do sacubitril-valsartan and ivabradine improve prognosis and outcomes in patients with HFrEF who are symptomatic on standard therapies?
Do sacubitril-valsartan and ivabradine improve prognosis and outcomes in patients with HFrEF who are symptomatic on standard therapies?
Sacubitril-valsartan and ivabradine provide important alternative treatment options for patients with HFrEF who remain symptomatic despite standard guideline-directed medical therapy.
Despite availability of standardized drug therapies with proven beneficial outcomes, heart failure is associated with poor quality of life, increased hospital readmission, and high mortality rate. In the recent years, comprehensive understanding of the pathophysiological mechanisms of heart failure has led to the development and approval of 2 new pharmacological agents, sacubitril-valsartan and ivabradine. These agents are currently approved for use in heart failure with reduced ejection fraction (HFrEF) and present as novel approaches to further improve prognosis and outcomes in patients with HF. They offer alternative treatment options for patients who are intolerant or continue to be symptomatic despite utilization of standard HF drug therapies at optimally tolerated dosages. A review of these 2 novel agents in HFrEF, including information on pivotal trials that led to its approval and its place in therapy for HFrEF, is presented.
No takes yet. Share an insight, caveat, or question.
Patel et al. (2016) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: